maker of tirzepatide Why Eli Lilly Stock Jumped to a Record High on Tuesday Lilly (maker of Zepbound) plans

Continuous GLP-1 Therapy as a Long-Term Solution Rather than treating GLP-1 therapy as temporary, evidence increasingly supports viewing it as ongoing management for weight and metabolic healthsimilar to how people manage blood pressure or cholesterol with continuous medication

The Precision Peptide Genetic Test ($99 after your first month of treatment) maps genetic variants in the GLP1R gene and 13 other metabolic pathways that influence how your body responds to semaglutide

These deliver more fuel per bite than high-volume, low-calorie foods like salads

E., Monsanto S

Effect of Metformin on Insulin Resistance in Adults with Type 1 Diabetes: A 26-week Randomized Double-blind Clinical Trial